Abstracts tagged "psoriasis"

Abstract Number: 2727 • 2016 ACR/ARHP Annual Meeting
Evaluating Psoriatic Arthritis and Psoriasis Skin Lesions: Ultrasound As a Complementary Measure
Yogan Kisten¹, Per T Larsson², Erik af Klint², Hamed Rezaei^2,3, Noémi Györi¹, Liv Eidsmo⁴, Mona Ståhle⁴ and Ronald F. van Vollenhoven^1,5, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Medicine, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ⁴Dermatology and Venereology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands
Background/Purpose: The diagnosis and assessment of psoriatic arthritis (PsA) and psoriasis (PsO) lesions are mostly done by visual inspection, and when in doubt, supplemented by…
Abstract Number: 960 • 2016 ACR/ARHP Annual Meeting
Ultrasonographic Improvement of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated with Ustekinumab for Chronic Plaque Psoriasis: A 52-Week, Prospective, Open Label, Controlled Cohort Study
Laura Savage¹, Mark Goodfield², Elizabeth M.A. Hensor³, Paul Emery³ and Dennis McGonagle⁴, ¹NIHR Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ²Department of Dermatology, Leeds Centre for Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Subclinical enthesopathy is recognised in up to 50% of psoriasis patients and is thought to precede inflammatory PsA. It is not known if effective…
Abstract Number: 2744 • 2016 ACR/ARHP Annual Meeting
Utilization of the Psoriasis Epidemiology Screening Tool (PEST) Questionnaire to Detect Psoriatic Arthritis in Clinical Practice: Data from the Validation of Psoriatic Arthritis Screening Tool for Korean Psoriasis Patients (VALOR) Study
You Jung Ha¹, Soyun Cho², Sang Heon Lee³, Yong Beom Choe⁴, Tae-Hwan Kim⁵, Joo Yeon Ko⁶, Sung Jae Choi⁷, Il-Hwan Kim⁸, Sang Woong Youn⁹ and Kichul Shin¹⁰, ¹Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, ²Department of Dermatology, Department of Dermatology, SMG-SNU Boramae Medical Center, Seoul, Korea, The Republic of, ³Department of Internal Medicine,Division of Rheumatology., Division of Rheumatology, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea, The Republic of, ⁴Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea, The Republic of, ⁵Department of Rheumatology, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁶Department of Dermatology, Department of Dermatology, Hanyang University College of Medicine, Seoul, Korea, The Republic of, ⁷Division of Rheumatology, Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea, The Republic of, ⁸Department of Dermatology, Korea University Ansan Hospital, Ansan, Korea, The Republic of, ⁹Department of Dermatology, Seoul National University Bundang Hospital, Seongnam, Korea, The Republic of, ¹⁰Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, The Republic of
Background/Purpose: Several questionnaires have been developed to help identify psoriatic arthritis (PsA) among patients with psoriasis (PsO), but there is no screening tool yet tested…
Abstract Number: 1239 • 2016 ACR/ARHP Annual Meeting
Optimizing Screening for Psoriatic Arthritis through a Shortened Psoriatic Arthritis Screening and Evaluation-2 (PASE-2) Tool
Jordan Thompson¹, Marwa Darwish², So Yeon Paek³, Joseph Merola⁴, Abrar Qureshi^1,3 and M. Elaine Husni⁵, ¹Dermatology, Alpert Medical School, Brown University, Providence, RI, ²No affiliation, Boston, MA, ³Dermatology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, ⁴Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology Dept A50, Cleveland Clinic, Cleveland, OH
Background/Purpose: The Psoriatic Arthritis Screening and Evaluation (PASE) Tool is one of the most frequently used tools to screen psoriasis patients for signs and symptoms…
Abstract Number: 2761 • 2016 ACR/ARHP Annual Meeting
Sleep Disturbance in Psoriatic Disease: Prevalence and Associated Factors
Ian Tin Yue Wong¹, Vinod Chandran², Suzanne Li³ and Dafna D Gladman⁴, ¹Faculty of Medicine, University of British Columbia, Vancouver,, BC, Canada, ²Medicine, Krembil Research Institute, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriasis is a chronic inflammatory skin disease characterized by scaling, erythematous plaques. Up to 30% of psoriasis patients develop an inflammatory arthritis termed psoriatic…
Abstract Number: 1301 • 2016 ACR/ARHP Annual Meeting
Analysis of Anatomical Sites Causing Dactylitis and Their Responsiveness to Change Under TNF-Therapy in Psoriatic Arthritis By High Resolution MRI
Dr. Philipp Sewerin, PD Dr. Stefan Vordenbäumen, Dr. Ruben Sengewein, Prof. Dr. Matthias Schneider and Prof. Dr. Benedikt Ostendorf, Department of Rheumatology & Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany
Background/Purpose: Results: The following sites were most commonly involved in dactylitis: collateral ligament enthesitis 11/12 (92%); extensor tendons enthesitis 5/12 (42%); flexor tenosynovitis 9/12 (75%),…
Abstract Number: 3096 • 2016 ACR/ARHP Annual Meeting
Association Between Smoking and Psoriatic Arthritis Among Psoriasis Patients and the General Population: Data from National Inpatient Sample
Paras Karmacharya¹, Dilli Poudel¹, Rashmi Dhital² and Pragya Shrestha³, ¹Internal Medicine, Reading Health System, WEST READING, PA, ²Universal College of Medical Sciences, MBBS, Kathmandu, Nepal, ³Internal medicine, Reading Health System, West Reading, PA
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis affecting approximately 520,000 patients in the US and up to one third of patients with psoriasis. Studies…
Abstract Number: 1422 • 2016 ACR/ARHP Annual Meeting
Identifying Generic and Specific Patients’ Perspectives on Disease- and Treatment-Related Issues in Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis: A Qualitative Concept Mapping Study
Tanja Schjødt Jørgensen¹, Louise Klokker¹, Henrik Gudbergsen², Simon Francis Thomsen³, Robin Christensen⁴, Henning Bliddal¹ and Lars Erik Kristensen¹, ¹The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ²The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg,, Copenhagen, Denmark, ³Department of Dermatology, Bispebjerg Hospital & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark
Identifying generic and specific patients’ perspectives on disease- and treatment-related issues in rheumatoid arthritis, psoriatic arthritis, and psoriasis: a qualitative concept mapping studyT.S. Jørgensen1, L.…
Abstract Number: 1668 • 2016 ACR/ARHP Annual Meeting
Selective Inhibition of Tumor Necrosis Factor-α Receptor 2 (TNFR2) Activity Alleviates Psoriasiform Inflammation in Mouse Models
Unnikrishnan Chandrasekharan¹, Chad Braley², Jennifer Harvey³, Zeneng Wang¹, Paul DiCorleto⁴ and M. Elaine Husni⁵, ¹Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH, ²Department of Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, ³Department of Cellular and Molecular, Cleveland Clinic, Cleveland, OH, ⁴Division of Research and Sponsored Programs, Kent State, kent, OH, ⁵Rheumatology, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Tumor necrosis factor-α (TNF) activates two receptors globally, TNFR1 and TNFR2. Neutralizing antibodies or soluble TNF receptors can inactivate TNF, blocking activity of both…
Abstract Number: 1688 • 2016 ACR/ARHP Annual Meeting
Ixekizumab Provides Sustained Improvement up to 52 Weeks of Disease Activity As Assessed By Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Laura C. Coates¹, M. Elaine Husni², Catherine L. Shuler³, Hilde Carlier³, Chen-Yen Lin³, Jiani Mou³, Chin H. Lee³ and Philip J Mease⁴, ¹University of Leeds, Leeds, United Kingdom, ²Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: PsA, a chronic immune-mediated inflammatory disease, can be progressive and destructive, resulting in physical deformities, impaired function, decreased quality of life, and increased mortality.…
Abstract Number: 1704 • 2016 ACR/ARHP Annual Meeting
Consistent Safety and Tolerability of Secukinumab over Long-Term Exposure in Patients with Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses
Philip J Mease¹, Iain B McInnes², Kristian Reich³, Mats Andersson⁴, Aiyang Tao⁵, Todd Fox⁴ and Chetan Karyekar⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Glasgow, Glasgow, Great Britain, ³Dermatologikum Hamburg and Georg-August-University Göttingen, Hamburg, Germany, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Pooled safety data from the psoriasis (PsO) and psoriatic arthritis (PsA) clinical trial programs of secukinumab (SEC), through approximately 1 year, have been reported…
Abstract Number: 1705 • 2016 ACR/ARHP Annual Meeting
The Risk of Fracture Among Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis
Lauren Harter¹, Daniel Shin², Joshua F. Baker³, Junko Takeshita², Thorvardur Love^4,5, Joel Gelfand⁶ and Alexis Ogdie⁷, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²University of Pennsylvania, Philadelphia, PA, ³Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁵Landspitali University Hospital, Reykjavík, Iceland, ⁶University of Pennsylvania Health System , Philadelphia, PA, ⁷Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: While rheumatoid arthritis (RA) has been linked to an increased incidence of osteoporosis (OP) and fracture, few studies have examined the risk of fracture…
Abstract Number: 1714 • 2016 ACR/ARHP Annual Meeting
Risk of 10-Year Cardiovascular Disease Assessed By Framingham Risk Score Is Similar in Patients with Psoriatic Arthritis and Psoriasis As Assessed By Atherosclerotic Cardiovascular Disease and Framingham Risk Scores
Natsumi Ikumi¹, Agnes Szentpetery¹, Brian Kirby² and Oliver FitzGerald¹, ¹St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ²St. Vincent's University Hospital, Department of Dermatology, Dublin, Ireland
Background/Purpose: Patients with psoriatic arthritis (PsA) and psoriasis (PsO) are at increased risk of cardiovascular diseases (CVD) and the risk is higher in patients with…
Abstract Number: 1719 • 2016 ACR/ARHP Annual Meeting
Secular Trends in Treatment Patterns for Psoriasis and Psoriatic Arthritis: A Population-Based Cohort Study
Joseph F Merola¹, Joyce Lii², Rishi J. Desai³, Daniel H. Solomon⁴ and Seoyoung C. Kim⁵, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medicine, Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁴Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Psoriasis (Pso) and psoriatic arthritis (PsA) are complex, multi-system diseases for which an ever-increasing landscape of therapies exists. Little is known about the population…
Abstract Number: 1726 • 2016 ACR/ARHP Annual Meeting
An Integrated Safety Data Analysis Across All Phase II and Phase III Clinical Programs for Ustekinumab in Psoriatic Arthritis, Crohn’s Disease, and Psoriasis
Lianne S. Gensler¹, Elizabeth C. Hsia², Christopher Gasink², Bruce Randazzo², Dennis Parenti³, Steve Fakharzadeh³, Kehzen L. Tang² and Soumya Chakravarty³, ¹Medicine/Rheumatology, UCSF, San Francisco, CA, ²Janssen Research & Development, LLC, Spring House, PA, ³Janssen Scientific Affairs, LLC, Horsham, PA
Background/Objective:Therapeutic decisions are based on efficacy, but clinicians need to consider medication safety in this process. Here, we report ustekinumab (UST) integrated safety data in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].